Literature DB >> 18709682

Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia.

Jaime Kulisevsky1, Javier Pagonabarraga, Berta Pascual-Sedano, Carmen García-Sánchez, Alexandre Gironell.   

Abstract

A cross-sectional study of the profile of psychiatric symptoms and their relationships to medications, executive performance, and excessive daytime somnolence (EDS) was conducted on 1351 consecutive Parkinson's disease patients without dementia (PD-ND). Ratings were: neuropsychiatric inventory (NPI); hospital anxiety and depression scale (HADS); executive performance (semantic, phonemic, and alternating verbal fluencies); and the Epworth sleepiness scale (ESS). Eighty-seven percent of the subjects reported at least one psychiatric symptom. The most common were depression (70%), anxiety (69%), apathy (48%), and irritability (47%). Fifty percent of the patients had HADS-depression scores ranging from possible (8-10; 22%) to probable (>or=11; 28%) depression. Executive impairment was found in 41% and EDS in 26% of subjects. All considered variables were significantly more common with longer duration and more severe disease. Only depression appeared to be influenced by type of medication, being less prevalent among patients treated with DAs. Five NPI clusters were identified among patients scoring >or=1 on the NPI (87.3%): patients exhibiting predominantly apathy (12.7%), psychosis (3%), depression (13%), anxiety (15.6%), and "low-total NPI" (43.2%). Neuropsychiatric symptoms are common in nondemented PD patients suggesting that they are an integral part of PD from the beginning of the disease and appears more related to disease progression than to the type of antiparkinsonian medication. Apathy emerged as an independent construct in PD-ND, indicating the need to address specific therapeutical approaches targeted toward this particular symptom. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Year:  2008        PMID: 18709682     DOI: 10.1002/mds.22246

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  63 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

2.  Emerging issues on selection criteria of levodopa carbidopa infusion therapy: considerations on outcome of 28 consecutive patients.

Authors:  Mariachiara Sensi; F Preda; L Trevisani; E Contini; D Gragnaniello; J G Capone; E Sette; N Golfre-Andreasi; V Tugnoli; M R Tola; R Quatrale
Journal:  J Neural Transm (Vienna)       Date:  2014-01-08       Impact factor: 3.575

Review 3.  Apathy in neuropsychiatric disease: diagnosis, pathophysiology, and treatment.

Authors:  Thomas N Chase
Journal:  Neurotox Res       Date:  2010-05-15       Impact factor: 3.911

4.  Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial.

Authors:  Roseanne D Dobkin; Matthew Menza; Lesley A Allen; Michael A Gara; Margery H Mark; Jade Tiu; Karina L Bienfait; Jill Friedman
Journal:  Am J Psychiatry       Date:  2011-06-15       Impact factor: 18.112

Review 5.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

6.  Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease.

Authors:  O Grau-Rivera; E Gelpi; M J Rey; F Valldeoriola; E Tolosa; Y Compta; M J Martí
Journal:  J Neurol       Date:  2013-09-18       Impact factor: 4.849

7.  Neuropsychiatric symptoms and striatal monoamine availability in early Parkinson's disease without dementia.

Authors:  Yoon-Sang Oh; Jean Hee Kim; Sang-Won Yoo; Eo-Jin Hwang; Chul Hyoung Lyoo; Kwang-Soo Lee; Joong-Seok Kim
Journal:  Neurol Sci       Date:  2020-10-31       Impact factor: 3.307

8.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

9.  Barriers to mental health care utilization in Parkinson's disease.

Authors:  Roseanne D Dobkin; Jade Tiu Rubino; Jill Friedman; Lesley A Allen; Michael A Gara; Matthew Menza
Journal:  J Geriatr Psychiatry Neurol       Date:  2013-04-15       Impact factor: 2.680

10.  Facial emotion recognition impairment in patients with Parkinson's disease and isolated apathy.

Authors:  Mercè Martínez-Corral; Javier Pagonabarraga; Gisela Llebaria; Berta Pascual-Sedano; Carmen García-Sánchez; Alexandre Gironell; Jaime Kulisevsky
Journal:  Parkinsons Dis       Date:  2010-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.